Table II.

Summary of possible mucocutaneous adverse effects reported for proposed COVID-19 treatments^∗

Treatment	Mucocutaneous adverse effects
Chloroquine/hydroxychloroquine†	•Common: itching, hair loss •Less common: morbilliform rash, erythroderma, exfoliative dermatitis, urticaria, eczematous eruption, erythema annulare centrifugum, photosensitivity •Rare: acute generalized exanthematous pustulosis
Azithromycin†	•Rare: morbilliform rash
Lopinavir/ritonavir	•Common: morbilliform rash •Rare: acute generalized exanthematous pustulosis, hair loss
Corticosteroids	•Common: skin atrophy, acneiform eruption, telangiectasia, petechiae, ecchymosis, striae, hirsutism
Tocilizumab	•Less common: anaphylaxis •Rare: morbilliform rash, erythroderma, leukocytoclastic vasculitis
Convalescent plasma	•Less common: morbilliform rash, itching, evanescent red spot

^∗References supporting this table are available from the corresponding author upon request.

^†Combination treatment increases the risk of QT prolongation.